Modality
Fusion Protein
MOA
PD-L1i
Target
EGFR
Pathway
T-cell
MGGA
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Jun 2026
Phase 1Current
NCT03015221
2,199 pts·GA
2025-03→2026-06·Active
NCT04361870
2,048 pts·GA
2017-01→TBD·Recruiting
4,247 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-203mo awayPh2 Data· GA
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2026-06-20 · 3mo away
GA
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03015221 | Phase 1/2 | GA | Active | 2199 | HbA1c |
| NCT04361870 | Phase 1/2 | GA | Recruiting | 2048 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |